三阴性乳腺癌的分析进展-普通外科学专业论文.docxVIP

PAGE PAGE 10 三阴性乳腺癌的研究进展 中文摘要 目的 探讨三阴性乳腺癌的最新研究进展 方法 通过归纳总结国内外最新文献资料，并作进一步的综合分析 结果 三阴性乳腺癌被定义为雌激素受体（ER）、孕激素受体（PR）和人表皮生长 因子受体-2（EGFR-2）均阴性的乳腺癌，它具有独特的生物学特性及临床特征。 大多数三阴性乳腺癌有基底细胞样表型的特点以及相同的临床病理特征，并且与 遗传性基因 BRCA1 相关。三阴性乳腺癌患者不同的亚群对于特定的靶向治疗有 着不同的疗效。我们评估了三阴性乳腺癌化疗联合靶向治疗的方案，系统评价了 PubMed 数据库上对接受了化疗、靶向治疗、新辅助治疗、放疗的乳腺癌女性患 者的随机临床试验报告。三阴性乳腺癌是一个对化疗敏感的实体肿瘤，单纯结合 靶向药物并不能使疗效显著的提高，合理地选择病人，理性地结合靶向药物，才 能使疗效获得成功。 结论 作为一个特殊类型的乳腺癌，三阴性乳腺癌的发病机制目前尚未知晓。临床 数据显示，风险因素，如种族，年龄，绝经状态，使用激素避孕药，组织学分级 高，和晚期疾病独立相关与三阴性乳腺癌呈正相关。因为没有具体的一线疗法， 研究人员主要致力于从不同方面,例如基因水平、激素受体、免疫调节、信号通路 等进行研究。由于该病的发病率较低，目前也有只有几个临床试验。因此，我们 期待在将来进行更大规模的临床试验。 关键词 乳腺癌 三阴性 基底细胞 靶向治疗 化疗 Advance In Triple-negative Breast Cancer Objective : Discuss the latest research progress of three negative breast cancer Methods：The latest domestic and foreign literature was summarized and analysised comprehensively Results ： Triple-negative breast cancer (TNBC) is defined by the lack of immunohistochemical expression of the estrogen and progesterone receptors and human epidermal growth factor receptor 2 (EGFR2). Most TNBC has a basal-like molecular phenotype by gene expression profiling and shares clinical and pathological features with hereditary BRCA1 related breast cancers. TNBC subgroups respond differentially to specific targeted agents. We evaluates the activity of available chemotherapy and targeted agents in TNBC. A systematic review of PubMed and conference databases was carried out to identify randomised clinical trials reporting outcomes in women with TNBC treated with chemotherapy and targeted agents. TNBC being a chemosensitive entity, combination with targeted agents have not produced substantial improvements in outcomes，reasonably select patients, combined with targeted drugs rationally, to make the curative effect of success. Conclusion：As a special type of breast cancer, the pathogenesis of TNBC is unknown at present. Clinical data showed that the risk factors, such as race, age, menopausal status, the use of hormona